IL244984B - Cancer treatment with a combination of palinabolin and taxane - Google Patents
Cancer treatment with a combination of palinabolin and taxaneInfo
- Publication number
- IL244984B IL244984B IL244984A IL24498416A IL244984B IL 244984 B IL244984 B IL 244984B IL 244984 A IL244984 A IL 244984A IL 24498416 A IL24498416 A IL 24498416A IL 244984 B IL244984 B IL 244984B
- Authority
- IL
- Israel
- Prior art keywords
- plinabulin
- taxane
- combination
- cancer treatment
- cancer
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title 1
- 229940123237 Taxane Drugs 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- UNRCMCRRFYFGFX-TYPNBTCFSA-N plinabulin Chemical compound N1C=NC(\C=C/2C(NC(=C\C=3C=CC=CC=3)/C(=O)N\2)=O)=C1C(C)(C)C UNRCMCRRFYFGFX-TYPNBTCFSA-N 0.000 title 1
- 229950011498 plinabulin Drugs 0.000 title 1
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/CN2013/085075 WO2015051543A1 (en) | 2013-10-11 | 2013-10-11 | Cancer treatment with combination of plinabulin and taxane |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL244984A0 IL244984A0 (en) | 2016-05-31 |
| IL244984B true IL244984B (en) | 2022-05-01 |
Family
ID=52812462
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL244984A IL244984B (en) | 2013-10-11 | 2016-04-07 | Cancer treatment with a combination of palinabolin and taxane |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US10596169B2 (OSRAM) |
| EP (1) | EP3076972B1 (OSRAM) |
| JP (1) | JP6411523B2 (OSRAM) |
| KR (1) | KR102225371B1 (OSRAM) |
| CN (1) | CN105705148B (OSRAM) |
| AU (1) | AU2013402794B2 (OSRAM) |
| BR (1) | BR112016007946A2 (OSRAM) |
| CA (1) | CA2926771C (OSRAM) |
| DK (1) | DK3076972T3 (OSRAM) |
| ES (1) | ES2902665T3 (OSRAM) |
| IL (1) | IL244984B (OSRAM) |
| MX (1) | MX384751B (OSRAM) |
| MY (1) | MY185650A (OSRAM) |
| NZ (1) | NZ719049A (OSRAM) |
| RU (1) | RU2662298C2 (OSRAM) |
| SG (1) | SG11201602637QA (OSRAM) |
| WO (1) | WO2015051543A1 (OSRAM) |
| ZA (1) | ZA201602380B (OSRAM) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2016219204B2 (en) * | 2015-02-12 | 2021-01-21 | Beyondspring Pharmaceuticals, Inc. | Use of Plinabulin in combination with immune checkpoint inhibitors |
| JP6769982B2 (ja) | 2015-03-06 | 2020-10-14 | ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド | Ｒａｓ変異と関連するがんの治療方法 |
| KR102623404B1 (ko) * | 2015-03-06 | 2024-01-11 | 비욘드스프링 파마수티컬스, 인코포레이티드. | 뇌 종양 치료 방법 |
| ES2910035T3 (es) | 2015-07-13 | 2022-05-11 | Beyondspring Pharmaceuticals Inc | Composiciones de plinabulina |
| CA3013467A1 (en) | 2016-02-08 | 2017-08-17 | Beyondspring Pharmaceuticals, Inc. | Compositions containing tucaresol or its analogs |
| EP3463337A4 (en) * | 2016-06-06 | 2020-02-12 | Beyondspring Pharmaceuticals, Inc. | COMPOSITION AND METHOD FOR REDUCING NEUTROPENIA |
| CN110431135A (zh) | 2017-01-06 | 2019-11-08 | 大连万春布林医药有限公司 | 微管蛋白结合化合物及其治疗用途 |
| KR20190109479A (ko) * | 2017-02-01 | 2019-09-25 | 비욘드스프링 파마수티컬스, 인코포레이티드. | 호중구감소증의 감소 방법 |
| SG11201908420WA (en) * | 2017-03-13 | 2019-10-30 | Beyondspring Pharmaceuticals Inc | Compositions of plinabulin and use thereof |
| CN109498627B (zh) * | 2017-09-15 | 2021-06-04 | 深圳华大海洋科技有限公司 | 一种治疗肿瘤的药物组合物及其应用 |
| SG11202006985TA (en) | 2018-01-24 | 2020-08-28 | Beyondspring Pharmaceuticals Inc | Composition and method for reducing thrombocytopenia via the administration of plinabulin |
| JP2021512121A (ja) * | 2018-02-01 | 2021-05-13 | ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド | プリナブリンおよびｇ−ｃｓｆ製剤の投与による化学療法誘発性好中球減少症を軽減するための組成物および方法 |
| CN108524442B (zh) * | 2018-06-05 | 2022-01-28 | 深圳海王医药科技研究院有限公司 | 一种抗肿瘤药物的注射剂及其制备方法 |
| JP2018199726A (ja) * | 2018-09-26 | 2018-12-20 | ビヨンドスプリング インコーポレイテッド | プリナブリン及びタキサンの組合せがん治療 |
| CN113661253B (zh) * | 2018-11-14 | 2024-03-12 | 大连万春布林医药有限公司 | 微管蛋白结合剂治疗癌症的方法 |
| CN110507653B (zh) * | 2019-08-02 | 2022-12-02 | 北京赛而生物药业有限公司 | 多潘立酮及其与紫杉醇联用在制备治疗癌症的药物中的应用 |
| EP4045046A4 (en) * | 2019-10-15 | 2024-01-10 | Beyondspring Pharmaceuticals Inc. | Methods and compositions for treating iron disorders |
| WO2022216908A1 (en) * | 2021-04-09 | 2022-10-13 | Beyondspring Pharmaceuticals, Inc. | Therapeutic compositions and methods for treating tumors |
| CN113456643B (zh) * | 2021-08-11 | 2022-04-01 | 遵义医科大学 | 一种含普那布林的药物组合及其应用 |
| CN117860672A (zh) * | 2022-10-11 | 2024-04-12 | 大连万春布林医药有限公司 | 一种普那布林胶束组合物及其制备方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7141603B2 (en) | 1999-02-19 | 2006-11-28 | The Regents Of The University California | Antitumor agents |
| US7012100B1 (en) | 2002-06-04 | 2006-03-14 | Avolix Pharmaceuticals, Inc. | Cell migration inhibiting compositions and methods and compositions for treating cancer |
| US7919497B2 (en) | 2002-08-02 | 2011-04-05 | Nereus Pharmaceuticals, Inc. | Analogs of dehydrophenylahistins and their therapeutic use |
| ES2295695T3 (es) | 2002-08-02 | 2008-04-16 | Nereus Pharmaceuticals, Inc. | Deshidrofenilahistinas y sus analogos y la sintesis de deshidrofenilahistinas y sus analogos. |
| JP2007520565A (ja) * | 2004-02-04 | 2007-07-26 | ネレアス ファーマシューティカルズ インコーポレイテッド | デヒドロフェニラヒスチン及びそれらの類似体、並びにデヒドロフェニラヒスチン及びそれらの類似体の合成 |
| GB0907551D0 (en) * | 2009-05-01 | 2009-06-10 | Univ Dundee | Treatment or prophylaxis of proliferative conditions |
| WO2014160183A1 (en) | 2013-03-13 | 2014-10-02 | The United States Of America,As Represented By The Secretary,Department Of Health And Human Services | Methods for modulating chemotherapeutic cytotoxicity |
-
2013
- 2013-10-11 AU AU2013402794A patent/AU2013402794B2/en active Active
- 2013-10-11 NZ NZ719049A patent/NZ719049A/en unknown
- 2013-10-11 MX MX2016004441A patent/MX384751B/es unknown
- 2013-10-11 DK DK13895342.7T patent/DK3076972T3/da active
- 2013-10-11 CA CA2926771A patent/CA2926771C/en active Active
- 2013-10-11 JP JP2016547208A patent/JP6411523B2/ja active Active
- 2013-10-11 WO PCT/CN2013/085075 patent/WO2015051543A1/en not_active Ceased
- 2013-10-11 RU RU2016112608A patent/RU2662298C2/ru active
- 2013-10-11 KR KR1020167012255A patent/KR102225371B1/ko active Active
- 2013-10-11 EP EP13895342.7A patent/EP3076972B1/en active Active
- 2013-10-11 SG SG11201602637QA patent/SG11201602637QA/en unknown
- 2013-10-11 CN CN201380080185.5A patent/CN105705148B/zh active Active
- 2013-10-11 ES ES13895342T patent/ES2902665T3/es active Active
- 2013-10-11 MY MYPI2016000620A patent/MY185650A/en unknown
- 2013-10-11 US US15/028,376 patent/US10596169B2/en active Active
- 2013-10-11 BR BR112016007946A patent/BR112016007946A2/pt not_active Application Discontinuation
-
2016
- 2016-04-07 IL IL244984A patent/IL244984B/en unknown
- 2016-04-08 ZA ZA2016/02380A patent/ZA201602380B/en unknown
-
2020
- 2020-03-17 US US16/821,348 patent/US20200281921A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20200281921A1 (en) | 2020-09-10 |
| MX384751B (es) | 2025-03-14 |
| EP3076972A1 (en) | 2016-10-12 |
| EP3076972A4 (en) | 2017-12-20 |
| KR102225371B1 (ko) | 2021-03-10 |
| IL244984A0 (en) | 2016-05-31 |
| DK3076972T3 (da) | 2022-01-03 |
| JP2016536352A (ja) | 2016-11-24 |
| RU2016112608A (ru) | 2017-11-16 |
| CN105705148B (zh) | 2021-03-23 |
| WO2015051543A8 (en) | 2016-04-21 |
| US20160250209A1 (en) | 2016-09-01 |
| WO2015051543A1 (en) | 2015-04-16 |
| AU2013402794A1 (en) | 2016-05-12 |
| KR20160078987A (ko) | 2016-07-05 |
| CN105705148A (zh) | 2016-06-22 |
| ZA201602380B (en) | 2022-05-25 |
| EP3076972B1 (en) | 2021-10-06 |
| AU2013402794B2 (en) | 2020-02-27 |
| SG11201602637QA (en) | 2016-05-30 |
| MX2016004441A (es) | 2016-10-28 |
| US10596169B2 (en) | 2020-03-24 |
| BR112016007946A2 (pt) | 2017-09-12 |
| MY185650A (en) | 2021-05-27 |
| CA2926771A1 (en) | 2015-04-16 |
| NZ719049A (en) | 2020-06-26 |
| CA2926771C (en) | 2022-07-05 |
| RU2662298C2 (ru) | 2018-07-25 |
| JP6411523B2 (ja) | 2018-10-24 |
| ES2902665T3 (es) | 2022-03-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201602380B (en) | Cancer treatment with combination of plinabulin and taxane | |
| IL273090B (en) | Methods and preparations for the treatment of cancer | |
| GB201320723D0 (en) | Composition and methods of treatment | |
| IL242386B (en) | Use of Aribolin and Lavetinib as a combination therapy for cancer treatment | |
| IL243215A0 (en) | Treatment of brain cancer with oncolytic adenoviruses | |
| PH12021552945A1 (en) | Treatment of cancer with dihydropyrazino-pyrazines | |
| ZA201507733B (en) | Treatment of cancer with dihydropyrazino-pyrazines | |
| PL3060211T3 (pl) | Leczenie nowotworu i łagodnych chorób proliferacyjnych | |
| IL238481A0 (en) | Cancer treatment using synthetic lethal approaches | |
| IL242533B (en) | Naltrexone cancer treatment | |
| PL2948137T3 (pl) | Sposoby leczenia zwłóknienia i nowotworów | |
| GB201403083D0 (en) | Treatment of cancer | |
| SG10201802995SA (en) | Cancer treatment with combination of plinabulin and taxane | |
| GB201317373D0 (en) | Treatment and prevention of cancer | |
| GB201301685D0 (en) | Diagnosis and treatment of cancer | |
| GB201322346D0 (en) | Combination treatment of cancer | |
| TWI561255B (en) | Use of umirolimus and its derivatives for treating cancer | |
| GB201322958D0 (en) | Uses of oligouronates in cancer treatment | |
| GB201322347D0 (en) | Treatment of cancer | |
| GB201318742D0 (en) | Treatment of cancer | |
| GB201308529D0 (en) | Treatment of cancer | |
| GB201305020D0 (en) | Treatment of cancer | |
| GB201303115D0 (en) | Detection and treatment of liver cancer |